Рецепторы, активирующие пролиферацию пероксисом, в физиологии и патологии легких


https://doi.org/10.18093/0869-0189-2013-0-2-95-100

Полный текст:


Аннотация

Рецепторы, активирующие пролиферацию пероксисом, в физиологии и патологии легких.


Об авторе

М. С. Расин
ВГУЗ "Украинская медицинская стоматологическая академия"
Украина

проф. кафедры внутренних болезней № 3 

36024, Украина, г. Полтава, ул. Шевченко, 23. Тел.: (380532) 676-269.



Список литературы

1. Bugge A., Mandrup S. Molecular Mechanisms and Genome-Wide Aspects of PPAR Subtype Specific Transactivation. PPAR Research. Volume 2010; Article ID 169506, doi: 10.1155/2010/169506.

2. Huang J.V., Greyson C.R., Schwartz G.G. PPAR-γ as a therapeutic target in cardiovascular disease: Evidence and uncertainty. J. Lipid. Res. 2012; 53 (9): 1738–1754.

3. Rehan V.K., Torday J.S. PPARγ Signaling Mediates the Evolution, Development, Homeostasis, and Repair of the Lung. PPAR Research. Volume 2012; Article ID 289867, doi:10.1155/2012/289867.

4. Torday J.S., Rehan V.K. Deconvoluting lung evolution using functional / comparative genomics. Am. J. Respir. Cell. Mol. Biol. 2004; 31: 8–12.

5. Torday J.S, Sun H., Wang L. et al. Leptin mediates the parathyroid hormone-related protein paracrine stimulation of fetal lung maturation. Am. J. Physiol. 2002; 282: L405–L410.

6. Liu J., Sakurai R., O'Roark E.M. et al. PPARγ agonist rosiglitazone prevents perinatal nicotine exposure-induced asthma in rat offspring. Am. J. Physiol. 2011; 300: L710–L717.

7. Escher P., Wahli W. Peroxisome proliferator-activated receptors: insight into multiple cellular functions. Mutat. Res. 2000; 448: 121–138.

8. Расін О.М. Молекулярні механізми протизапальної дії глітазонів та статинів: роль PPAR-γ. Міжнарод. ендокринол. журн. 2007; 6 (12): 71–76.

9. Кайдашев И.П. NF-κB-сигнализация как основа развития системного воспаления, инсулинорезистентности, липотоксичности, сахарного диабета 2-го типа и атеросклероза Международ. эндокринол. журн. 2011; 3 (35): 35–40.

10. Ohshima K., Mogi M., Horiuchi M. Role of peroxisome proliferator-activated receptor-γ in vascular inflammation. J. Intern. Vasc. Med. 2012. Internet resource. Volume. 2012.

11. Hirabara S.M. et al. Molecular Targets Related to Inflammation and Insulin Resistance and Potential Interventions. J. Biomed. Biotechnol. Internet resource. Volume 2012.

12. Spinelli S.L., O'Brien J.J., Bancos S. et al. The PPAR-platelet connection: modulators of inflammation and potential cardiovascular effects. PPAR Res. 2008; Article ID 328172.

13. Patel H.J., Belvisi M.G., Bishop+Bailey D. et al. Activation of peroxisome proliferator-activated receptors in human airway smooth muscle cells has a superior anti-inflammatory profile to corticosteroids: relevance for chronic obstructive pulmonary disease therapy. J. Immunol. 2003; 170: 2663–2669.

14. Nie M., Corbett L., Knox A.J., Pang L. Differential regulation of chemokine expression by peroxisome proliferatoractivated receptor gamma agonists: Interactions with glucocorticoids and beta 2-agonists. J. Biol. Chem. 2004; 324: 47.

15. Belvisi M.G., Hele D.J., Birrell M.A. Peroxisome proliferator-activated receptor gamma agonists as therapy for chronic airway inflammation. Eur. J. Pharmacol. 2006; 533: 101–109.

16. Lee S.Y., Kang E.J., Hur G.Y. et al. Peroxisome proliferatoractivated receptor-γ inhibits cigarette smoke solutioninduced mucin production in human airway epithelial (NCI-H292) cells. Am. J. Physiol. Lung Cell. Mol. Physiol. 2006; 291: L84–L90.

17. Honda K., Marquillies P., Capron M., Dombrowicz D. Peroxisome proliferator-activated receptor-γ is expressed in airways and inhibits features of airway remodeling in a mouse asthma model. J. Allergy Clin. Immunol. 2004: 113: 882–888.

18. Hammad H., de Heer H.J., Soullie T. et al. Activation of peroxisome proliferator-activated receptor-γ in dendritic cells inhibits the development of eosinophilic airway inflammation in a mouse model of asthma. Am. J. Pathol. 2004; 164: 263–271.

19. Lee K.S., Park S.J., Kim S.R. et al. Modulation of airway remodeling and airway inflammation by peroxisome proliferator-activated receptor γ in a murine model of toluene diisocyanate-induced asthma. J. Immunol. 2006; 177: 5248–5257.

20. Milam J.E., Keshamouni V.G., Phan S.H. et al. PPARgamma agonists inhibit pro-fibrotic phenotypes in human lung fibroblasts and bleomycin-induced pulmonary fibrosis. Am. J. Physiol. Lung Cell. Mol. Physiol. 2008; 294: L891–L901.

21. Hogan C.M., Thatcher T.H., Sapinoro R.E. et al. Electrophilic PPARγ ligands attenuate IL-1β and silica-induced inflammatory mediator production in human lung fibroblasts via a PPARγ-independent mechanism. PPAR Res. 2011; Article ID 318134.

22. Michalik L., Desvergne B., Wahli W. Peroxisome-proliferator-activated receptors and cancers: complex stories. Nature Rev. Cancer 2004; 4 (1): 61–70.

23. Ward J.E., Fernandes D.J., Taylor C.C. et al. The PPARγ ligand, rosiglitazone, reduces airways hyperresponsiveness in a murine model of allergen-induced inflammation. Pulm. Pharmacol. Ther. 2006; 19 (1): 39–46.

24. Stegenga M.E., Florquin S., de Vos A.F., van der Poll T. The thiazolidinedione ciglitazone reduces bacterial outgrowth and early inflammation during streptococcus pneumonia pneumonia in mice. Crit. Care Med. 2009; 37 (2): 614–618.

25. Belvisi J.A.M., Maria G. Targeting PPAR receptors in the airway for the treatment of inflammatory lung disease. Br. J. Pharmacol. 2009; 158 (4): 994–1003.

26. Becker J., Delayre+Orthez C., Frossard N., Pons F. Regulation of inflammation by PPARs: a future approach to treat lung inflammatory diseases? Fundam. Clin. Pharmacol. 2006; 20: 429–447.

27. Cuzzocrea S., Bruscoli S., Mazzon E. et al. PPAR-alpha contributes to the anti-inflammatory activity of glucocorticoids. Mol. Pharmacol. 2007; 73: 323–337.

28. Reddy R.C., Rehan V.K., Roman J., Sime P.J. PPARs: Regulators and translational targets in the lung. PPAR Res. 2012; Article ID 342924. doi: 10.1155/2012/342924.

29. Чучалин А.Г. Идиопатический легочный фиброз. Тер. арх. 2000; 3: 5– 12.

30. Burgess H.A., Daugherty L.E., Thatcher T.H. et al. PPAR-gamma agonists inhibit TGF-induced pulmonary myofibroblast differentiation and collagen production: implications for therapy of fibrosis. Am. J. Physiol. Lung Cell. Mol. Physiol. 2005; 288: 1146–1153.

31. Delayre+Orthez C., Becker J., Auwerx J. et al. PPAR-alpha decreases airway inflammation associated with asthma in the mouse. Fundam. Clin. Pharmacol. 2004; 18: 220.

32. Lakatos H.F., Thatcher T.H., Kottmann R.M. et al. The role of PPARs in lung fibrosis. PPAR Res. 2007; Article ID 71323.

33. Чучалин А.Г. Новые перспективы лечения тяжелой бронхиальной астмы: в фокусе внимания атопия. Здоров'я України 2008; 9 (1): 32–33.

34. Kohansal R., Martinez+Camblor P., Agustí A. et al. The natural history of chronic airflow obstruction revisited: an analysis of the Framingham Offspring Cohort. Am. J. Respir. Crit. Care Med. 2009; 180 (1): 3–10.

35. Амелина Е.Л., Черняк А.В., Чучалин А.Г. Муковисцидоз взрослых: особенности ведения. Пульмонология 2006; прил. по муковисцидозу: 30–35.

36. Lee S.Y., Kang E.J., Hur G.Y. et al. Peroxisome proliferatoractivated receptor-γ inhibits cigarette smoke solutioninduced mucin production in human airway epithelial (NCI-H292) cells. Am. J. Physiol. 2006; 291 (1): L84–L90.

37. Liu D.S., Liu W.J., Chen L. et al. Rosiglitazone, a peroxisome proliferator-activated receptor-γ agonist, attenuates acrolein-induced airway mucus hypersecretion in rats. Toxicology 2009; 260 (1–3): 112–119.

38. Yongchun S., Wen F. PPARγ as a potential target to treat airway mucus hypersecretion in chronic airwayю inflammatory diseases. PPAR Res. 2012; Article ID 256874. doi: 10.1155/2012/256874.

39. Lee J.+M., Kim S.S., Cho Y.+S. The role of PPARγ in helicobacter pylori infection and gastric carcinogenesis. PPAR Res. 2012; Article ID 687570.

40. Han S., Roman J. Rosiglitazone suppresses human lung carcinoma cell growth through PPARγ-dependent and PPARγ-independent signal pathways. Mol. Cancer Ther. 2006; 5 (2): 430–437.

41. Kulkarni A.A., Woeller C.F., Thatcher T.H. et al. Emerging PPARγ-Independent Role of PPARγ Ligands in Lung Diseases. PPAR Res. 2012; Article ID 705352.

42. Keshamouni V.G., Reddy R.C., Arenberg D.A. et al. Peroxisome proliferator-activated receptor-γ activation inhibits tumor progression in non-small-cell lung cancer. Oncogene 2004; 23 (1): 100–108.

43. Colin C., Salamone S., Grillier+Vuissoz I. et al. New troglitazone derivatives devoid of PPARγ agonist activity display an increased antiproliferative effect in both hormone-dependent and hormone-independent breast cancer cell lines. Breast Cancer Res. Treat. 2010; 124 (1): 101–110.

44. Fulzele S.V., Chatterjee A., Shaik M.S. et al. 15-Deoxy-δ12,14-prostaglandin J2 enhances docetaxel anti-tumor activity against A549 and H460 non-small-cell lung cancer cell lines and xenograft tumors. Anti-Cancer Drug 2007; 18 (1): 65–78.

45. Liby K., Voong N., Williams C.R. et al. The synthetic triterpenoid CDDO-Imidazolide suppresses STAT phosphorylation and induces apoptosis in myeloma and lung cancer cells. Clin. Cancer Res. 2006; 12 (14): 4288–4293.

46. Wright H.M., Clish C.B., Mikami T. et al. A synthetic antagonist for the peroxisome proliferator-activated receptor-γ inhibits adipocyte differentiation. J. Biol. Chem. 2000; 275 (3); 1873–1877.

47. Girnun G.D., Chen L., Silvaggi J. et al. Regression of drugresistant lung cancer by the combination of rosiglitazone and carboplatin. Clin. Cancer Res. 2008; 14 (20): 6478–6486.

48. Pioglitazone hydrochloride in treating patients with stage I, stage II, or stage III non-small cell lung cancer. Clinical Trials. Gov Identifier: NCT01342770.


Дополнительные файлы

Для цитирования: Расин М.С. Рецепторы, активирующие пролиферацию пероксисом, в физиологии и патологии легких.  Пульмонология. 2013;(2):95-100. https://doi.org/10.18093/0869-0189-2013-0-2-95-100

For citation: Rasin M.S. Peroxisome proliferator-activated receptors in physiology and pathology of the lung. Russian Pulmonology. 2013;(2):95-100. (In Russ.) https://doi.org/10.18093/0869-0189-2013-0-2-95-100

Просмотров: 253

Обратные ссылки

  • Обратные ссылки не определены.


ISSN 0869-0189 (Print)
ISSN 2541-9617 (Online)